Claraphi Advisory Network, LLC Zynerba Pharmaceuticals, Inc. Transaction History

Claraphi Advisory Network, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$3.23 - $4.3 $80,485 - $107,147	-24,918 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$3.31 - $6.54 $69,225 - $136,777	20,914 Added 522.33%	24,918 $84,000
Q1 2020 May 15, 2020	SELL	$2.9 - $6.16 $22,185 - $47,124	-7,650 Reduced 65.64%	4,004 $15,000
Q4 2019 Feb 13, 2020	SELL	$5.61 - $8.57 $17,334 - $26,481	-3,090 Reduced 20.96%	11,654 $70,000
Q3 2019 Nov 08, 2019	SELL	$7.56 - $15.44 $20,858 - $42,598	-2,759 Reduced 15.76%	14,744 $111,000
Q2 2019 Jul 29, 2019	BUY	$5.4 - $15.5 $29,872 - $85,746	5,532 Added 46.21%	17,503 $237,000
Q1 2019 May 13, 2019	BUY	$3.6 - $6.22 $43,095 - $74,459	11,971 New	11,971 $65,000

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Claraphi Advisory Network, LLC, based on Form 13F filings with the SEC.

Stay updated on Claraphi Advisory Network, LLC with notifications on news.